Shots:
- Innate Pharma to present interim P-II (MATISSE) data (n=40) for IPH5201 at AACR Annual Meeting 2026, highlighting early efficacy in resectable NSCLC
- IPH5201 (anti-CD39) combined with durvalumab and chemotherapy showed promising pathological complete response (pCR) rates of 35.7% (PD-L1 ≥1%) and 50% (PD-L1 ≥50%)
- The study continues enrollment in PD-L1–positive pts., supporting further evaluation of dual CD39 and PD-L1 inhibition as a perioperative immunotherapy strategy
Ref: Innate Pharma | Image: Innate Pharma | Press Release
Related News: The US FDA Grants Breakthrough Therapy Designation to Innate Pharma’s Lacutamab for R/R Sézary Syndrome
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
